NSE · ROSSARI · Basic Materials
Rossari Biotech Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹482 Cr with net profit ₹34 Cr — a 7.11% net margin, versus 10.6% the period before.
Shareholding
As of 2026-06-30
- Promoter68.14%
- Public15.2%
- FII2.02%
- DII14.64%
87,580 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.9× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Chemicals · ranked #44 of 159 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Pidilite Industries Ltd. | ₹1,65,890 Cr | 67.35 | 15.31 | 22.61% | 16.77% |
| Solar Industries India Ltd. | ₹1,63,362 Cr | 93.51 | 26.02 | 26.72% | 17.05% |
| SRF Ltd. | ₹77,213 Cr | 34.46 | 5.5 | 13.07% | 13.01% |
| Linde India Limited | ₹56,603 Cr | 103.24 | 13.27 | 12.87% | 21.69% |
| Gujarat Fluorochemicals Ltd. | ₹48,279 Cr | 443.04 | 6.19 | 7.3% | 11.49% |
| Godrej Industries Ltd. | ₹44,101 Cr | 99.27 | 3.95 | 11.1% | 5.58% |
| Himadri Speciality Chem Limited | ₹38,370 Cr | 191.08 | 8.15 | 15.96% | 16.12% |
| Navin Fluorine International Ltd. | ₹37,898 Cr | 58.47 | 9.53 | 16.69% | 20.02% |
| Deepak Nitrite Ltd. | ₹22,422 Cr | 102.04 | 3.84 | 9.43% | 6.98% |
| Atul Ltd. | ₹20,029 Cr | 95.31 | 3.22 | 9.31% | 8.93% |
| Rossari Biotech Limited(this company) | ₹2,812 Cr | 18.65 | 2.11 | 11.19% | 5.91% |
AI analysis
AI-generated · google/gemini-2.5-flashRossari Biotech Limited is listed with a market capitalization of Rs 2872 Cr. For the financial year ending March 2026, the company reported revenue of Rs 2418.74 Cr and a net profit of Rs 149.21 Cr. Its profit margin stood at 6.23%. The company's revenue grew by 13.6% during this period.
Positives
- +The company's revenue grew by 13.6% as of March 2026.
- +The debt-to-equity ratio is low at 0.26.
- +Promoter shareholding is substantial at 68.15% as of March 31, 2026.
- +No promoter shares are pledged, with promoter pledge at 0%.
Negatives
- −The profit margin is relatively thin at 6.23% for the financial year ending March 2026.
- −Promoter shareholding has decreased from 72.69% in September 2020 to 68.15% in March 2026.
- −FII shareholding has significantly decreased from 7.82% in June 2021 to 2.18% in March 2026.
- −Quarterly net profit decreased from Rs 45.97 Cr in March 2026 to Rs 35.1 Cr in June 2026.
Financial Performance
For the financial year ending March 2026, Rossari Biotech Limited recorded a revenue of Rs 2418.74 Cr, reflecting a growth of 13.6%. The net profit for the same period was Rs 149.21 Cr. The EPS for Mar 2026 was Rs 26.93. Quarterly revenue for the period ending June 2026 was Rs 697.2 Cr with a net profit of Rs 35.1 Cr.
Profitability & Returns
The company's profit margin for the financial year ending March 2026 was 6.23%. Return on equity (ROE) stood at 11.19%, and return on capital employed (ROCE) was 13.06%. The EPS for the financial year ending March 2026 was Rs 26.93.
Balance Sheet
Rossari Biotech Limited has a book value of Rs 240.7. The debt-to-equity ratio is 0.26, indicating a relatively low level of debt compared to equity. No information regarding specific assets or liabilities is provided in the available data.
Ownership & Pledges
The promoter shareholding has decreased from 72.69% in September 2020 to 68.15% in March 2026. No promoter shares are pledged.
Regulatory & Surveillance
The company is not currently under any surveillance measure according to the provided data. There is no information provided about any regulatory actions or inquiries.
Data as of — price: 2026-07-30 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.